Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Why Moderna's Cancer Vaccine Matters To Investors

BY | ETF Database
7:41 am ET 09/02/26 | 5 VIEWS
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient’s unique biology. Recent clinical results from Moderna, Inc. (MRNA) bring this shift into sharp focus.Key Takeaways Moderna and Merck achieved a historic breakthrough with the first successful late-stage trial for a personalized mRNA cancer vaccine, validating the broader shift toward individualized oncology. Delivering custom therapies requires a deeply interconnected ecosystem, where groundbreaking medical innovations rely on specialized hardware, software, and manufacturing technologies from across the broader healthcare landscape. As legacy pharmaceutical models face structural challenges such as patent cliffs, targeting the underlying technology enablers of next-generation care offers a compelling approach for healthcare investors. This transition is one of the driving forces behind the strategy of the Healthcare Technology and Innovation Index (HTEC), specifically within its precision medicine subsegment. Here the index captures the innovators developing custom therapies that account for an individual’s genetic profile, environmental factors, and lifestyle. *Denotes a current HTEC constituent.Moderna Cancer Vaccine Trial Results: Reducing Melanoma RecurrenceModerna*, in partnership with Merck & Co., Inc. (MRK), announced successful results from its clinical trial for intismeran, a personalized mRNA cancer vaccine targeting melanoma. This achievement marks the world’s first success in a late-stage trial for a personalized mRNA cancer therapy. This is major news. Moderna stock surged 176.97% on the day of the announcement, not only because this is a new treatment for a deadly type of cancer, but because it signals a viable new technology for oncology. Beyond melanoma, Moderna is already conducting trials to apply this same mRNA technology to other conditions, including lung, bladder, and renal cell carcinomas. The recent trial focused on patients whose cancer had been completely surgically removed and who, under the current standard of care, face a high likelihood of recurrence. It is estimated that approximately 112,000 new cases of melanoma will be diagnosed in the U.S. in 2026 alone, leading to over 8,500 deaths. This late-stage success validates data from an earlier study, which showed that by combining the immunotherapy drug KEYTRUDA with the personalized mRNA therapy from Moderna, patients experienced a 49% reduction in the risk of recurrence or death, and a 59% reduction in the risk of distant metastasis (when the cancer spreads to other organs). These results address a critical unmet need. Despite surgical advances, many patients face a high probability of the cancer returning within two years. Most recurrences are metastatic, emphasizing the need for treatments that improve long-term outcomes.From Biopsy to Bedside: The Companies Powering Personalized Cancer VaccinesThe HTEC strategy recognizes that breakthroughs of this magnitude do not occur in isolation. They are supported by an interconnected network of cutting-edge technologies. For intismeran, the treatment process begins with identifying the patient’s unique tumor mutations. Moderna utilizes the genomic sequencing platform from Personalis (recently acquired by Tempus AI, Inc. (TEM)* ). That platform in turn runs on sequencing hardware from Illumina, Inc. (ILMN)*. Moderna uses this tech stack to identify up to 34 targetable neoantigens, which are unique protein markers on cancer cells that enable the immune system to recognize and target the disease. The physical production of the vaccine then relies on specialized partners. Danaher Corporation (DHR)* provides the essential DNA templates required to print the mRNA, while Thermo Fisher Scientific Inc. (TMO)* packages the final medicine into sterile vials. This entire process comes only after diagnosis. Diagnosis is achieved using dermatopathology solutions from companies like Roche Holding AG (ROG)*, which facilitates early and accurate disease detection. The ecosystem’s reach extends even earlier in the patient journey through companies like Natera, Inc. (NTRA)*. Their hereditary cancer testing identifies genetic risks for melanoma, encouraging proactive screening that catches the disease when early intervention is most effective. This seamless collaboration across diagnostics, genomics, and process automation shows that bringing precision medicine from biopsy to bedside requires an entire interconnected ecosystem, not just a single drug maker.Positioning Your Portfolio for the Precision Medicine EraIntismeran is more than just a win for Moderna; it highlights how cancer care is increasingly moving past the one-size-fits-all model. It also shows that building a therapy tailored to an individual is not something a single pharma company can do alone. Delivering custom care requires diagnostic screeners, sequencing platforms, and high-tech manufacturers all working in tandem. This collaborative reality is why HTEC targets the full technological ecosystem rather than traditional pharma giants. The index selects companies based on their market and technological leadership. It also looks for companies with revenue purity across proprietary subsegments that, like precision medicine, are deemed essential to the future of healthcare. Precision medicine represents just one pillar of this strategy. However, it underscores why HTEC focuses on future technological impact rather than legacy revenue. In doing so, the index provides investors with diversified exposure to next-generation care.Related ResearchCyclosporiasis: Investing in Biosecurity 3 Companies Redefining Healthcare Innovation Healthcare Exposure Focused on Big Pharma? You’re Missing Out HTEC is the underlying index for the Robo Global Healthcare Technology & Innovation ETF (HTEC) and the L&G Healthcare Technology & Innovation UCITS ETF (DOCT.LN). Looking for regular updates? Subscribe here for weekly insights on Healthcare Technology, AI, and Robotics, delivered straight to your inbox. For more news, information, and analysis, visit our Disruptive Technology Content Hub. VettaFi is the index provider for HTEC ETF and DOCT.LN, for which it receives an index licensing fee. However, HTEC ETF and DOCT.LN are not issued, sponsored, endorsed, or sold by VettaFi. VettaFi and its affiliates have no obligation or liability in connection with the issuance, administration, marketing, or trading of HTEC ETF and DOCT.LN.

More Commentary

ETF Acquisitions Surge: Goldman, Victory, & T. Rowe Price Expand
BY | ETF Database
8:42 am ET 09/02/26 | 0 VIEWS
XLE Tops August Sector Rankings as Energy Stocks Surge
BY | ETF Database
5:41 am ET 09/02/26 | 18 VIEWS
Tap Into Back-to-School Spending With This Retail ETF
BY | ETF Database
7:53 am ET 09/02/26 | 2 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.